NZ Liver Cancer Research Review Issue 3
In this issue:
– ESMO clinical practice guideline for the management of HCC
– Anlotinib + penpulimab vs sorafenib for first-line treatment of unresectable HCC
– Addition of tiragolumab to atezolizumab + bevacizumab in patients with HCC
– Liver cancer in 2021: Global Burden of Disease study
– Optimising treatment selection for early HCC
– Ipilimumab + anti-PD-1/ PD-L1 combination therapy in advanced HCC
– Is the current surveillance strategy suitable for all patients and disease types?
– Abbreviated MRI vs ultrasound for detecting early-stage HCC
– Immunotherapy before liver transplant in high-risk patients with HCC
Expert contributor
Dr Jeffrey Ngu
Dr Jeffrey Ngu (MB ChB, FRACP, PhD) is a consultant gastroenterologist and hepatologist at Christchurch Hospital and a senior lecturer at the University of Otago, Christchurch. His research interests include autoimmune liver diseases, MASLD, viral hepatitis and gastrointestinal haemorrhage.
Expert contributor
Dr Nikki Burnand
Nikki is a general medical oncologist, currently practicing in Wellington Regional Hospital. Her main sub interest is gastrointestinal cancers. Nikki is a Clinical Senior Lecturer at the University of Otago School of Medicine.
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.
